Lv51
1170 积分 2020-08-12 加入
Ponatinib–Blinatumomab or Imatinib–Chemotherapy for Adult Ph-Positive ALL
6天前
已完结
Genomic and clinical landscape of RAS mutations in acute myeloid leukemia
6天前
已完结
Liposomal-Mitoxantrone Overcomes Acquired Resistance and Enhances Venetoclax Synergy in AML-Mechanistic Insights and Preliminary Clinical Evidence
7天前
已完结
Intensive Chemotherapy and Tyrosine Kinase Inhibitor in Patients with De Novo BCR::ABL1+ Acute Myeloid Leukemia
7天前
已完结
GAMMA: A genetic–clinical prognostic model for risk stratification in patients with relapsed/refractory acute myeloid leukemia receiving allogeneic hematopoietic stem cell transplantation
14天前
已完结
Measurable residual disease assessment as an early end point of treatment efficacy in acute myeloid leukemia: a multinational PETHEMA study of 2623 patients treated with intensive therapy
14天前
已完结
KMT2D, a key factor in driving cellular transformation and influencing therapeutic response across cancer lineages
24天前
已关闭
How I Treat: MRD testing to personalize allogeneic HCT for adults with AML
29天前
已完结
Venetoclax Plus Hypomethylating Agent for 7‐ Versus 14‐ Versus 21‐ Versus 28‐Day Cycles in Newly‐Diagnosed Acute Myeloid Leukemia: ELN and Mayo Genetic Risk–Stratified Analysis in 540 Patients
1个月前
已完结
Intensive Chemotherapy and Tyrosine Kinase Inhibitor in Patients with De Novo BCR::ABL1+ Acute Myeloid Leukemia
1个月前
已关闭
皖公网安备34019202002308
